Antimicrobial peptide derivative and use thereof
US-2025249110-A1 · Aug 7, 2025 · US
Vascular endothelial growth factor [VEGF]
Vascular endothelial growth factor [VEGF] · Cooperative Patent Classification (CPC)
Agriculture, food, personal care, health, and life sciences.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | A61K39/001135 |
| Official title | {Vascular endothelial growth factor [VEGF]} |
| Display label | Vascular endothelial growth factor [VEGF] |
| Total patents | 62 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is declining.
| Year | Patents |
|---|---|
| 2015 | 4 |
| 2016 | 6 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 8 |
| 2020 | 9 |
| 2021 | 9 |
| 2022 | 6 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 5 |
| 2026 | 1 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereof
US-12234295-B2 · Feb 25, 2025 · US
Her-1, her-3 and igf-1r compositions and uses thereof
US-2025059256-A1 · Feb 20, 2025 · US
Methods Of Associating Genetic Variants With A Clinical Outcome In Patients Suffering From Age-Related Macular Degeneration Treated With Anti-VEGF
US-2025002978-A1 · Jan 2, 2025 · US
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US-12116622-B2 · Oct 15, 2024 · US
Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
US-11883398-B2 · Jan 30, 2024 · US
High-affinity anti-VEGF antibody KLHa505
US-11872271-B2 · Jan 16, 2024 · US
Combinations including ABX196 for the treatment of cancer
US-11826372-B2 · Nov 28, 2023 · US
Combinations of cancer therapeutics
US-2023248695-A1 · Aug 10, 2023 · US
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
US-11690910-B2 · Jul 4, 2023 · US
Chimeric cytokine receptor
US-2023133682-A1 · May 4, 2023 · US
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US-11519020-B2 · Dec 6, 2022 · US
Methods for treating cancer or modulating T cells or NK cells in a subject with cancer by administering cells comprising chimeric cytokine receptors
US-11479614-B2 · Oct 25, 2022 · US
Methods for treating cancer or modulating T cells or NK cells in a subject by administering cells comprising chimeric transmembrane proteins
US-11479613-B2 · Oct 25, 2022 · US
Combinations including abx196 for the treatment of cancer
US-2022193089-A1 · Jun 23, 2022 · US
Combinations including ABX196 for the treatment of cancer
US-11278552-B2 · Mar 22, 2022 · US
Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
US-11229645-B2 · Jan 25, 2022 · US
Methods Of Associating Genetic Variants With A Clinical Outcome In Patients Suffering From Age-Related Macular Degeneration Treated With Anti-VEGF
US-2021340605-A1 · Nov 4, 2021 · US
Methods and Compositions for Enhancing Vaccine Immune Responses
US-2021299236-A1 · Sep 30, 2021 · US
High-affinity anti-vegf antibody
US-2021228700-A1 · Jul 29, 2021 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC A61K39/001135?
- CPC A61K39/001135 is the Cooperative Patent Classification code for “Vascular endothelial growth factor [VEGF].”
- How many patents are filed under CPC A61K39/001135 (Vascular endothelial growth factor [VEGF])?
- Our database includes 62 publications tagged with this CPC code.
- Is patent activity under CPC A61K39/001135 growing?
- Publication counts under this code: 3 in 2024 vs 5 in 2025 (latest complete years).